Pfiz­er inks a back-end­ed $250M deal for skin-tar­get­ed JAK, pays $25M to set up the next leg of their he­mo­phil­ia A R&D jour­ney — while Bio­Marin jock­eys for first OK

→ Pfiz­er wants to find out a lot more about Ther­a­vance’s ap­proach to de­vel­op­ing spe­cial­ly tar­get­ed JAK in­hibitors. The phar­ma gi­ant is pay­ing $10 mil­lion up­front and promis­ing up to $240 mil­lion more to get li­cens­ing rights to the biotech’s pro­gram for an an­ti-in­flam­ma­to­ry JAK aimed at skin. Michael Vin­cent, Pfiz­er’s chief sci­en­tif­ic of­fi­cer for In­flam­ma­tion & Im­munol­o­gy, not­ed: “Top­i­cal JAK in­hibitors that can be rapid­ly me­tab­o­lized have po­ten­tial to reach more pa­tients with mild-to-mod­er­ate skin con­di­tions, for whom treat­ment is cur­rent­ly lim­it­ed.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER